Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel

BACKGROUND: In recent years treatment options for advanced pancreatic cancer have markedly improved, and a combination regimen of gemcitabine and nab-paclitaxel is now considered standard of care in Sweden and elsewhere. Nevertheless, a majority of patients do not respond to treatment. In order to g...

Descripción completa

Detalles Bibliográficos
Autores principales: Blomstrand, Hakon, Green, Henrik, Fredrikson, Mats, Gränsmark, Emma, Björnsson, Bergthor, Elander, Nils O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530950/
https://www.ncbi.nlm.nih.gov/pubmed/33008332
http://dx.doi.org/10.1186/s12885-020-07426-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530950/
https://www.ncbi.nlm.nih.gov/pubmed/33008332
http://dx.doi.org/10.1186/s12885-020-07426-8

Ejemplares similares